Galecto terminates development for its lead candidate
The Phase IIb trial in idiopathic pulmonary fibrosis for GB0139 did not meet its endpoint.
16 August 2023
16 August 2023
The Phase IIb trial in idiopathic pulmonary fibrosis for GB0139 did not meet its endpoint.
A highly statistically significant and clinically relevant benefit in eGFR was observed in the treatment group, compared to a placebo.
The FDA's accelerated approval for the bispecific antibody is based on the results from a single-arm Phase II study in multiple myeloma.
NA-831 was efficacious in lowering depressive and anxious symptoms in patients who received the treatment for six weeks.
The biopharma reported potent anti-tumour activity in preclinical models earlier this year.
The study will determine the recommended Phase II dose that can be used further in the studies.
The investigational therapy ADI-PEG 20 will be assessed at clinical trial sites in Canada, Europe, Australia and the US.
Outsourcing in Clinical Trials Southern California Conference 2023 will be returning to Hyatt Regency La Jolla at Aventine, USA on the 26th-27th September 2023! Focusing on interactive discussions to provide insight into the current major operational issues with running clinical trials in the coming years.
Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.
Give your business an edge with our leading industry insights.